Ozempic and Acid Reflux: Why It Happens and What Actually Helps

Short answer: Semaglutide (Ozempic and Wegovy) can make reflux more likely for some people, mostly early on and during dose increases. The increase large studies find is real but modest, and the absolute numbers are small. Smaller meals, an earlier last meal, and simple breathing habits before and after you eat all help.

In this post

  • Does Ozempic cause acid reflux? What the big studies show

  • How common is heartburn on semaglutide?

  • Why it happens: slower stomach emptying, and why it often eases

  • What helps

  • When to call your prescriber

  • The takeaway

If you started Ozempic or Wegovy and now have heartburn, burping, or a burn in your throat you didn't have before, you're probably asking two questions: is the medication the reason, and will it last? Below is what the research shows, including the places where it disagrees with itself, and what you can do while you and your prescriber decide what's right for you.

A quick note on names. Ozempic and Wegovy are both semaglutide. Ozempic is the diabetes brand, used at lower doses. Wegovy is the weight-loss brand, at 2.4 mg. I'll tell you which dose each study used, because it matters. (Mounjaro and Zepbound are tirzepatide, a related medication. For the basics across all of them, start with my GLP-1 and acid reflux guide.)

Does Ozempic cause acid reflux? What the big studies show

Three large analyses looked at this question, and they don't fully agree.

The trial data. A 2025 meta-analysis in Gastroenterology pooled 55 placebo-controlled randomized trials with 106,395 people. It looked at GLP-1 medications as a group, not semaglutide alone. GLP-1s had a relative risk of GERD of 2.19 compared with placebo. Relative risk sounds alarming, so look at the absolute number: about 4 more cases of GERD for every 1,000 people. The authors rated the risk as "probably increased."

A large real-world study. A 2025 study in Annals of Internal Medicine used UK health records to compare 24,708 people with type 2 diabetes who started a GLP-1 with 89,096 who started an SGLT2 inhibitor (a different type of diabetes medication). GLP-1 users had a relative risk of GERD of 1.27, an absolute difference of 0.7 per 100 people over 3 years. This was an observational study designed to mimic a trial, and everyone in it had type 2 diabetes, so it shows an association in that group.

A study that found no increase for semaglutide's group. A 2024 study in Gut used a large health records database and matched 177,666 people with type 2 diabetes in each group. Overall, GLP-1 users had a hazard ratio of 1.15 for erosive reflux (reflux that has damaged the lining of the esophagus). When the researchers split the medications by how long they act, the long-acting group, which includes semaglutide, had a hazard ratio of 0.994, meaning no increase. The overall rise came from the shorter-acting medications. This was also an observational study looking back at records, mostly in type 2 diabetes.

Put together, the evidence conflicts. The pooled trials point to a modest increase, one observational study agrees, and another finds no increase for the long-acting medications semaglutide belongs to. My read: semaglutide can raise reflux risk for some people, the increase is modest, and the absolute numbers are small.

How common is heartburn on semaglutide?

The clearest picture of day-to-day symptoms comes from the Wegovy trials. The official Wegovy prescribing information pools three randomized, placebo-controlled trials of semaglutide 2.4 mg lasting up to 68 weeks, with 2,116 people on the medication and 1,261 on placebo. Here's how often reflux-type symptoms showed up:

  • GERD: 5% on semaglutide vs 3% on placebo

  • Dyspepsia (indigestion): 9% vs 3%

  • Eructation (burping): 7% vs under 1%

Burping is the one people least expect. If it's new for you and it comes with heartburn or a sour taste, mention it to your prescriber.

A 2022 analysis of the main Wegovy trials (STEP 1 to 3) adds two reassuring findings. 98.1% of GI side effects were mild to moderate, and most happened during or shortly after dose escalation, the weeks when the dose is being stepped up. Keep in mind that all of these rates come from the 2.4 mg (Wegovy) dose.

Why it happens: slower stomach emptying, and why it often eases

GLP-1 medications slow how quickly your stomach empties. When food stays in your stomach longer, your stomach stays fuller, and that fullness puts pressure on your lower esophageal sphincter (LES), the valve that keeps stomach contents where they belong. More pressure gives reflux more chances to happen.

How much does semaglutide slow emptying? The studies differ:

  • A small trial that found a big effect. A 2023 trial of 20 women with PCOS on semaglutide 1.0 mg (an Ozempic dose) found that 37% of a test meal was still in the stomach at 4 hours, compared with 0% on placebo. It's a tiny study in one specific group, using the 1.0 mg dose.

  • A larger trial that found no detectable delay. A 2021 trial of 72 adults on semaglutide 2.4 mg found "no evidence of delayed gastric emptying" at week 20, measured indirectly with a paracetamol (acetaminophen) absorption test.

  • An older GLP-1 that showed the slowing fade. A 2017 trial of 40 adults on liraglutide found stomach emptying was delayed by a median of 70 minutes at week 5, but only 30.5 minutes at week 16. Liraglutide is a different medication, so this can't prove the same happens on Ozempic. What it does show is that with an older GLP-1, the slowing faded over weeks.

That pattern lines up with the side effect data above, where symptoms cluster around starting and stepping up the dose. For you, it means the first weeks and each dose increase are when meal habits matter most.

What helps

Start with food. Smaller meals, protein first, moderate fat, fluids between meals, and a last meal well before bed all reduce how much is sitting in your stomach. I walk through a full day of breakfasts, snacks, lunches and dinners in what to eat on a GLP-1 with acid reflux.

Then add two breathing practices I teach my clients. They are two different habits: one before you eat and one after.

Before meals: the 5+1 Method. Before your first bite, take five slow breaths, then name one thing you're grateful for. Slow breathing shifts your nervous system toward rest-and-digest, the state your body digests best in, so your stomach starts the meal ready to work.

After meals: the LES Lock. After you eat, sit upright and do 1 to 5 minutes of diaphragmatic breathing, up to 5 times a day. As you inhale, let your rib cage expand 360 degrees: front, sides and back. Your crural diaphragm, the part of the diaphragm that wraps around the esophagus where it meets the stomach, works alongside the LES as part of your reflux barrier, and this is how I teach clients to put it to work after a meal.

Neither practice has been studied in people taking GLP-1s. They're tools from my practice, and they cost you nothing to try.

When to call your prescriber

Call your prescriber if you notice any of these:

  • Vomiting that won't stop, or you can't keep fluids down for 24 hours

  • Food that feels stuck, or trouble swallowing

  • Severe upper-belly or back pain

  • Waking up choking or coughing

  • Black stools or vomiting blood

Please don't change your dose on your own. That decision belongs to you and your prescriber together.

The takeaway

Semaglutide can make reflux more likely for some people. The increase is modest, the absolute numbers are small, and symptoms are most likely early on and around dose increases. Focus on what you control: meal size, meal timing, five slow breaths before you eat, and an LES Lock after.

If you're on Ozempic or Wegovy and reflux is making it hard to stay the course, you don't have to white-knuckle it. Our team of reflux dietitians builds plans that work alongside your medication. Apply to work 1:1 at https://www.mollypelletier.com/acid-reflux-specialist.

With love,

Molly Pelletier, MS, RD

Verified Citations

  • Chiang CH, Jaroenlapnopparat A, Colak SC, et al. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025;169(6):1268-1281. PMID 40499738. https://doi.org/10.1053/j.gastro.2025.06.003

  • Noh Y, Yin H, Yu OHY, Bitton A, Azoulay L. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med. 2025;178(9):1268-1278. PMID 40658955. https://doi.org/10.7326/ANNALS-24-03420

  • Liu BD, Udemba SC, Liang K, et al. Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study. Gut. 2024;73(2):246-254. PMID 37739778. https://doi.org/10.1136/gutjnl-2023-329651

  • Novo Nordisk. WEGOVY (semaglutide) injection, Prescribing Information, Adverse Reactions table for weight reduction (3 placebo-controlled trials, up to 68 weeks; placebo n=1,261, Wegovy 2.4 mg n=2,116). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

  • Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. PMID 34514682. https://doi.org/10.1111/dom.14551

  • Jensterle M, Ferjan S, Ležaič L, et al. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obes Metab. 2023;25(4):975-984. PMID 36511825. https://doi.org/10.1111/dom.14944

  • Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. PMID 33269530. https://doi.org/10.1111/dom.14280

  • Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2(12):890-899. PMID 28958851. https://doi.org/10.1016/S2468-1253(17)30285-6

Previous
Previous

Coming Off Ozempic: Will My Acid Reflux Go Away?

Next
Next

What to Eat on a GLP-1 When You Have Acid Reflux (A Dietitian's Sample Day)